| XLS |
|
|
|
|
|
€ million |
Q1 – 2012 |
Q1 – 2011 |
|
Profit after tax |
176.6 |
344.2 |
|
Available-for-sale financial assets |
|
|
|
Fair value adjustments |
– |
25.2 |
|
Reclassification to income statement |
– |
–4.4 |
|
Deferred taxes |
– |
0.8 |
|
Changes recognized in equity |
– |
21.6 |
|
Derivative financial instruments |
|
|
|
Fair value adjustments |
25.6 |
11.8 |
|
Reclassification to income statement |
42.0 |
2.1 |
|
Deferred taxes |
–10.1 |
–0.6 |
|
Changes recognized in equity |
57.5 |
13.3 |
|
Actuarial gains and losses from defined benefit obligations and similar obligations |
|
|
|
Changes in actuarial gains and losses |
–1.0 |
– |
|
Deferred taxes |
– |
– |
|
Changes recognized in equity |
–1.0 |
– |
|
Exchange differences on translating foreign operations |
|
|
|
Changes taken directly to equity |
–19.4 |
–69.1 |
|
Reclassification to income statement |
– |
3.5 |
|
Changes recognized in equity |
–19.4 |
–65.6 |
|
Gains/losses recognized immediately in equity |
37.1 |
–30.7 |
|
Comprehensive income |
213.8 |
313.5 |
|
of which attributable to Merck KGaA shareholders |
211.5 |
312.6 |
|
of which attributable to non-controlling interest |
2.3 |
0.9 |